Tissue treatment methods

Abstract
Methods are provided herein for affecting a region of a subject's body, comprising exposing the region to a cooling element under conditions effective to cool subcutaneous adipose tissue in said region; and increasing the blood flow rate to the cooled tissue by exposing the tissue to an energy source. Methods are also provided for treating subcutaneous adipose tissue in a region of a subject's body, comprising exposing said region to a cooling element under conditions effective to cool said tissue; and exposing the tissue to an energy source to increase the blood flow rate to the cooled tissue, thereby stimulating reperfusion in, and/or causing an ischemia-reperfusion injury to, the cooled tissue.
Description
FIELD OF THE INVENTION

The present invention relates generally to methods for treating mammalian tissue, to subcutaneous adipose tissue treatment methods, and particularly to those involving cooling of the tissue.


BACKGROUND OF THE INVENTION

Excess body fat increases the likelihood of developing various types of diseases such as heart disease, high blood pressure, osteoarthrosis, bronchitis, hypertension, diabetes, deep-vein thrombosis, pulmonary emboli, varicose veins, gallstones, hernias, and several other conditions.


In addition to being a serious health risk, excess body fat can also detract from personal appearance and athletic performance. For example, excess body fat can form cellulite, which causes an “orange peel” effect at the surface of the skin. Cellulite forms when subcutaneous fat protrudes into the dermis and creates dimples where the skin is attached to underlying structural fibrous strands. Cellulite and excessive amounts of fat are often considered to be unappealing. Thus, in light of the serious health risks and aesthetic concerns associated with excess fat, an effective way of controlling excess accumulation of body fat is urgently needed.


Liposuction is a method for selectively removing body fat to sculpt a person's body. Liposuction is typically performed by plastic surgeons and dermatologists using specialized surgical equipment that mechanically removes subcutaneous fat cells via suction. One drawback of liposuction is that it is a serious surgical procedure, and the recovery may be painful. Liposuction can have serious and occasionally even fatal complications. In addition, the cost for liposuction is usually substantial.


Conventional non-invasive treatments for removing excess body fat typically include topical agents, weight-loss drugs, regular exercise, dieting, or a combination of these treatments. One drawback of these treatments is that they may not be effective or even possible under certain circumstances. For example, when a person is physically injured or ill, regular exercise may not be an option. Similarly, weight-loss drugs or topical agents are not an option when they cause an allergic or negative reaction. Furthermore, fat loss in selective areas of a person's body cannot be achieved using general or systemic weight-loss methods.


Other non-invasive treatment methods include applying heat to a zone of subcutaneous lipid-rich cells. U.S. Pat. No. 5,948,011 discloses altering subcutaneous body fat and/or collagen by heating the subcutaneous fat layer with radiant energy while cooling the surface of the skin.


Another method of reducing subcutaneous fat cells is to cool the target cells as disclosed in U.S. Patent Publication No. 2003/0220674 or in U.S. Patent Publication No. 2005/0251120, the entire disclosures of which are incorporated herein. These publications disclose, among other things, reducing the temperature of lipid-rich subcutaneous fat cells to selectively affect the fat cells without damaging the cells in the epidermis. Although these publications provide promising methods and devices, several improvements for enhancing the implementation of these methods and devices would be desirable.


In medicine, ischemia is a restriction in blood supply, generally due to factors in the blood vessels, with resultant damage or dysfunction of tissue. Since oxygen is mainly bound to hemoglobin in red blood cells, insufficient blood supply causes tissue to become hypoxic, or, if no oxygen is supplied at all, anoxic. This can cause necrosis and cell death. Ischemia is a feature of heart diseases, transient ischemic attacks, cerebrovascular accidents, ruptured arteriovenous malformations, and peripheral artery occlusive disease. Tissues that are especially sensitive to inadequate blood supply include the heart, the kidneys, and the brain.


Restoration of blood flow after a period of ischemia is generally recognized to actually be more damaging than the ischemia itself. The absence of oxygen and nutrients from blood creates a condition in which the restoration of circulation results in inflammation and oxidative damage from the oxygen (i.e., reperfusion injury) rather than restoration of normal function. Reintroduction of oxygen also causes a greater production of damaging free radicals. With perfusion injury, necrosis can be greatly accelerated.


SUMMARY OF THE INVENTION

In one aspect, the present invention provides methods and devices that use ischemia-reperfusion injury to reduce or eliminate fat cells in the human body. Although it is generally considered desirable to minimize ischemia-reperfusion injury to cells in the human body, it is believed, while not intending to be bound by theory, that it is beneficial to effect ischemia-reperfusion injury in adipose tissue, thus enhancing adipose tissue necrosis or apoptosis.


In certain embodiments, the present invention thus provides methods for affecting a region of a subject's body, comprising exposing an epidermal layer in said region to a cooling element under conditions effective to cool subcutaneous adipose tissue in said region; and increasing the rate of blood flow to the cooled tissue by exposing the tissue to an energy source.


In another embodiment, the invention provides methods of treating subcutaneous adipose tissue in a region of a subject's body, comprising exposing said region to a cooling element under conditions effective to cool said tissue; and stimulating reperfusion in the cooled tissue by exposing the tissue to an energy source to increase the blood flow rate to the cooled tissue.


The present invention also provides methods of treating subcutaneous adipose tissue in a region of a subject's body, comprising exposing said region to a cooling element under conditions effective to cool said tissue; and causing an ischemia-reperfusion injury to the cooled tissue by exposing the tissue to an energy source to increase the blood flow rate to the cooled tissue.


In still another embodiment, the present invention provides cooling methods for selective reduction of lipid-rich cells in a region of a human subject's body, comprising applying a cooling element proximal to the subject's skin to reduce the temperature within a local region containing the lipid-rich cells sufficiently to selectively reduce the lipid-rich cells of said region, and concurrently therewith maintain the subject's skin at a temperature wherein non-lipid-rich cells proximate to the cooling element are not reduced; and subsequent to applying a cooling element, applying an energy source to the cooled tissue to thereby increase a rate of blood flow to the cooled tissue.


In another embodiment, the present invention provides methods for selective reduction of lipid-rich cells in a region of a human subject's body, comprising selectively causing vasoconstriction in adipose tissue; and subsequently stimulating reperfusion by applying an energy source to thereby increase blood flow to the region.


In still another embodiment, the present invention provides methods for selectively creating ischemia in lipid-rich cells in a region of a human subject's body, and subsequently stimulating reperfusion by applying an energy source to thereby increase the blood flow.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic of a system for providing cooling or heating to a subject according to one embodiment of the present invention.



FIG. 2 is a schematic of a fluid control unit for the system of FIG. 1.



FIG. 3 is a schematic of an alternative fluid control unit for the system of FIG. 1.



FIG. 4 shows an alternative system for providing cooling or heating to a subject.



FIGS. 5-8 are isometric views of a temperature control device.



FIG. 9 is an exploded isometric view of the temperature control device of FIG. 5.



FIG. 10 is a block diagram showing computing system software modules for removing heat from subcutaneous lipid-rich cells in accordance with an embodiment of the invention.





The figures are provided by way of example and are not intended to be limiting.


DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

In one embodiment, the present invention provides methods for affecting a region of a subject's body, comprising exposing an epidermal layer in said region to a cooling element under conditions effective to cool subcutaneous adipose tissue in said region; and increasing the blood flow rate to the cooled tissue by exposing the tissue to an energy source.


In certain embodiments, the methods further comprise cycling at least one of the steps of exposing said region to a cooling element and increasing blood flow. For example, after a cycle of exposing said region to a cooling element and increasing blood flow, a step of exposing said region to a cooling element could be repeated. Alternatively, a step of increasing blood flow could be added.


In certain embodiments, the methods of the invention further comprise increasing vasoconstriction in the adipose tissue. This can be achieved by various mechanical, chemical means or certain cooling conditions. Certain drugs can be administered orally or injected into the adipose tissue to increase vasoconstriction. Epinephrine is an example of one vasoconstrictive drug that is commonly injected. Other examples include norepinephrine, catecholamines, epinephrine isoproterenol, dopamine, ephedrine, phenylephrine, amphetamine, metraminol, methoxamine, ergot alkaloids, ergonovine, methylergonavine, methysergide, and ergotamine. A mechanical means for increasing vasoconstriction would be by application of pressure to the region.


For purposes of this specification, “affecting” means affecting, disrupting, shrinking, disabling, destroying, removing, killing, or otherwise being altered. As mentioned above, cooling subcutaneous adipose tissue may result in disruption and eventual death of the adipocytes.


The term “subject,” as used herein, includes any animal having blood, adipose tissue, and an epidermis. In preferred embodiments, the subject is a human or some other mammal, even more preferably a non-infant human.


The term “temperature control element” refers to any structure that is able to effect an increase or reduction in temperature of an area or object of interest. A temperature control element that effects a reduction in temperature is, thus, a “cooling element.” In one embodiment, the temperature control element is actively cooled or heated, as with a fluid bath or the Peltier (thermoelectric) elements that are known in the art to create cold and warm surfaces dependent upon the application of voltage. FIG. 1 shows one type of active cooling or heating system 10, comprising a hot bath 12 and a cold bath 14 in fluid communication with an applicator 16. It is understood that the term bath is not intended to limit the fluid to water. For example, the cold bath 14 could receive a fluid comprising alcohol, glycol, or mixtures of water/alcohol or water/glycol. The baths include heating or cooling means, temperature sensors, and feedback control systems to maintain selected temperatures. In one embodiment, the hot bath is about 45° C. and the cold bath is about −5° C.


Depending on the type of fluids circulated through the applicator 16, a wide temperature range can be achieved at the applicator 16. The applicator 16 can be formed from a variety of thermoconductive materials, including copper, aluminum, or alloys, and is applied to a subject's epidermis. Alternatively, the applicator 16 could be formed from a relatively thin layer of nonconductive material, such as urethane. A fluid control unit 18 is disposed between the baths and the applicator to control the applicator temperature.



FIG. 2 provides a schematic for the fluid control unit 18, including fluid lines, a pump, a pair of valves, and logic (not depicted) for opening and closing the valves. In one embodiment, when cooling is desired, the valves route the fluid from the cold bath 14 to the pump, which circulates the fluid through the applicator and then back to the cold bath. Similarly, when heating is desired, the valves route the fluid from the hot bath 12 to the pump, which circulates the fluid through the applicator and then back to the hot bath.


Referring to FIG. 3, an alternative fluid control unit 18′ is depicted, including fluid lines, a pump, three valves, and logic (not depicted) for opening and closing the valves. In one embodiment, when cooling is desired, Valve 2 is opened, while valves Valve 1 and V3 are shut. Thus, the pump draws the fluid from the cold bath 14, which circulates the fluid through the applicator 16 and then back to the cold bath through a fluid long loop 20. It is understood that fluid long loop 20 is of a sufficient length and/or diameter that when valve V3 is open, the vast majority of the fluid passes through valve V3 and out to the hot bath 12. However, when valve V3 is closed, the system pressure drives the fluid through the long loop 20 and to the cold bath 14.



FIG. 4 depicts another system 100 for removing heat from subcutaneous lipid-rich cells of a subject 101 in accordance with the invention. The system 100 can include a cooling device 104 placed at an abdominal area 102 of the subject 101 or another suitable area for removing heat from the subcutaneous lipid-rich cells of the subject 101.


The system 100 can further include a cooling unit 106 and supply and return fluid lines 108a-b connecting the cooling device 104 to the cooling unit 106. The cooling unit 106 can remove heat from a coolant to a heat sink and provide a chilled coolant to the cooling device 104 via the fluid lines 108a-b. Examples of the circulating coolant include water, glycol, synthetic heat transfer fluid, oil, a refrigerant, and any other suitable heat conducting fluid. The fluid lines 108a-b can be hoses or other conduits constructed from polyethylene, polyvinyl chloride, polyurethane, and other materials that can accommodate the particular circulating coolant. The cooling unit 106 can be a refrigeration unit, a cooling tower, a thermoelectric chiller, or any other device capable of removing heat from a coolant. Alternatively, a municipal water supply (i.e., tap water) can be used in place of the cooling unit.


The cooling device 104 includes a plurality of thermoelectric cooling elements, such as Peltier-type thermoelectric elements, which can be individually controlled to create a custom spatial cooling profile and/or a time-varying cooling profile. The system 100 can further include a power supply 110 and a processing unit 114 operatively coupled to the cooling device 104. In one embodiment, the power supply 110 can provide a direct current voltage to the thermoelectric cooling device 104 to effectuate a heat removal rate from the subject 101. The processing unit 114 can monitor process parameters via sensors (not shown) placed proximate to the cooling device 104 through power line 116 to adjust the heat removal rate based on the process parameters. The heat transfer rate can be adjusted to maintain constant process parameters. Alternately, the process parameters can vary either spatially or temporally. The processing unit 114 can be in direct electrical communication through line 112, or alternatively, may be connected via a wireless communication: Alternatively, the processing unit 114 can be preprogrammed to provide a spatially distributed cooling profile and/or a time-varying cooling profile. The processing unit 114 can include any processor, Programmable Logic Controller, Distributed Control System, and the like.


In another aspect, the processing unit 114 can be in electrical communication with an input device 118, an output device 120, and/or a control panel 122. The input device 118 can include a keyboard, a mouse, a touch screen, a push button, a switch, a potentiometer, and any other device suitable for accepting user input. The output device 120 can include a display screen, a printer, a medium reader, an audio device, and any other device suitable for providing user feedback. The control panel 122 can include indicator lights, numerical displays, and audio devices. In alternative embodiments, the control panel 122 can be contained on the cooling device 104. In the embodiment shown in FIG. 4, the processing unit 114, power supply 110, control panel 122, cooling unit 106, input device 118, and output device 120 are carried by a rack 124 with wheels 126 for portability. In alternative embodiments, the processing unit 114 can be contained on the cooling device 104. In another embodiment, the various components can be fixedly installed at a treatment site.



FIGS. 5-8 are isometric views of one preferred cooling device 104. In this embodiment, the cooling device 104 includes a control system housing 202 and cooling element housings 204a-g. The control system housing 202 includes a sleeve 308 (FIG. 9) that may slide into collar 310 and/or may mechanically attach to the cooling element housings. The cooling element housings 204a-g are connected to heat exchanging elements (not shown) by attachment means 206. The attachment means can be any mechanical attachment device such as a screw or pin as is known in the art. The plurality of cooling element housings 204a-g can have many similar features. As such, the features of the first cooling element housing 204a are described below with reference symbols followed by an “a,” corresponding features of the second cooling element housing 204b are shown and noted by the same reference symbol followed by a “b,” and so forth. The cooling element housing 204a can be constructed from polymeric materials, metals, ceramics, woods, and/or other suitable materials. The example of the cooling element housing 204a shown in FIGS. 5-8 is generally rectangular, but it can have any other desired shape.


The cooling device 104 is shown in a first relatively flat configuration in FIG. 5; in a second slightly curved configuration in FIG. 6; and in a third curved configuration in FIG. 7. As shown in FIGS. 6 and 7, each segment of the cooling element housings 204a-g are rotatably connected to adjacent segments and moveable about connection 207a-f to allow the cooling device 104 to curve. The connection 207a-f, for example, can be a pin, a ball joint, a bearing, or other type of rotatable joints. The connection 207 can accordingly be configured to rotatably couple the first cooling element housing 204a to the second cooling element housing 204b. According to aspects of the invention, the first cooling element housing 204a can rotate relative to the second cooling element housing 204b (indicated by arrow A), each adjacent moveable pair of cooling elements being such that, for example, the angle between the first and second cooling element housings 204a and 204b can be adjusted up to a particular angle, for example 45°. In this way, the cooling device is articulated such that it can assume a curved configuration conformable to the skin of a subject.


One advantage of the plurality of rotatable heat exchanging surfaces is that the arcuate shape of the cooling device may concentrate the heat transfer in the subcutaneous region. For example, when heat exchanging surfaces are rotated about a body contour of a subject, the arcuate shape can concentrate heat removal from the skin.


The control system housing 202 can house a processing unit for controlling the cooling device 104 and/or fluid lines 108a-b and/or electrical power and communication lines. The control system housing 202 includes a harness port 210 for electrical and supply fluid lines (not shown for purposes of clarity). The control system housing 202 can further be configured to serve as a handle for a user of the cooling device 104. Alternatively, the processing unit may be contained at a location other than on the cooling device.


As shown in FIGS. 5-7, the cooling device 104 can further include at each end of the cooling device 104 retention devices 208a and 208b coupled to a frame 304. The retention devices 208a and 208b are rotatably connected to the frame by retention device coupling elements 212a-b. The retention device coupling elements 212a-b, for example, can be a pin, a ball joint, a bearing, or other type of rotatable joints. Alternatively, the retention devices 208a and 208b can be rigidly affixed to the end portions of the cooling element housings 204a and 204g. Alternately, the retention device can attach to control system housing 202.


The retention devices 208a and 208b are each shown as tabs 214, each having a slot 216 therein for receiving a band or elastomeric strap (not shown for purposes of clarity) to retain the cooling device 104 in place on a subject 101 during treatment. Alternatively, the cooling device may not contain any attached retention device and may be held in place by hand, may be held in place by gravity, or may be held in place with a band, elastomeric strap, or non-elastic fabric (e.g., nylon webbing) wrapped around the cooling device 104 and the subject 101.


In an alternate embodiment, the device may be a device for applying pressure, or otherwise inducing vasoconstriction, rather than a cooling device.


As shown in FIGS. 5-7, the cooling element housings 204a-g have a first edge 218 and an adjacent second edge 220 of a reciprocal shape to allow the cooling device 104 to mate and, thus, configure in a flat configuration. The first edge 218 and the second edge 220 are generally angular in the Figures; however, the shape could be curved, straight, or a combination of angles, curves, and straight edges that provide a reciprocal shape between adjacent segments of the cooling element housings 204a-g.



FIG. 8 shows an isometric view of an alternative cooling device 104 in accordance with embodiments of the invention suitable for use in the system 100. In this embodiment, the cooling device 104 includes a plurality of heat exchanging elements 300a-g contained within a flexible substrate 350. As described with respect to FIGS. 5-7, adjacent heat exchanging elements 300a-g are fluidly coupled in series by fluid lines 328.


The cooling elements 302a-g can be affixed to the flexible substrate 350, or may be embedded in the flexible substrate 350. The flexible substrate 350 can be constructed from polymeric materials, elastomeric materials, and/or other suitable materials. The flexible substrate 350 can further be an elastomer such as silicone or urethane or can be a fabric, such as nylon. The flexible substrate 350 can also be a thin polymer such as polypropylene or ABS. The example of the flexible substrate 350 shown in FIG. 8 is generally rectangular, but can have any other desired shape, including a matrix configuration or an anatomy specific shape.


As designed, the interface members and cooling elements protect the thermoelectric coolers while maintaining good heat transfer between the thermoelectric coolers and the skin. The interface members are sized such that they do not present a significant thermal mass. In one design, each thermoelectric cooler could be 1″×1.5″. The interface member or aluminum plate could also be 1″×1.5″ with a thickness of 0.04″. If the thermoelectric coolers' cooling power is approximately 10 W, which is appropriate based on the heat flux expected to conduct from the skin, then the aluminum plate would cool from an ambient temperature of 20° C. to a treatment temperature of −10° C. in about 7 seconds. The change in internal energy of the plate is described by the following equation:

ΔE=ρ·V·C·ΔT


where ΔE is the change in internal energy, ρ is the material density, V is the material volume, C is the heat capacity of the material, and ΔT is the temperature change. In the problem described above, the volume of the aluminum plate is V=1 in×1.5 in×0.04 in or 0.06 in3 (9.8×10-7 m3). For a typical grade of aluminum, C.°=875 J/kg*° C. and ρ=2770 kg/m3.


Solving the equation using these constants:

ΔE=2770 kg/m3*9.8−10-7m3*875 J/kg*° C.*30° C.=71.3 J


If the thermoelectric coolers have a cooling power of 10 W, then 71.3 J could be removed from the aluminum plate in 7.1 seconds, as is shown in the calculation below:

71.3 J/(10 J/second)=7.13 seconds


A small gap or recess in the frame at the skin surface may be included in one embodiment. Prior to applying the cooling device to the skin, a thermally conducting fluid or coupling agent can be applied to the device and to the skin to minimize contact resistance and increase heat transfer between the cooling device and the skin. This coupling agent will fill the gap in the cooling device and allow for limited lateral conduction between the thermoelectric coolers' plates. This will create a more uniform temperature gradient across the surface area of the skin when the cooling is applied to the skin.


The lipid-rich cells can be affected by disrupting, shrinking, disabling, destroying, removing, killing, or otherwise being altered. Without being bound by theory, selectively affecting lipid-rich cells is believed to result from localized crystallization of lipids at temperatures that do not induce crystallization in non-lipid-rich cells. The crystals can disrupt or alter the bi-layer membrane of lipid-rich cells to selectively damage these cells. Thus, damage of non-lipid-rich cells, such as dermal cells, can be avoided at temperatures that induce crystal formation in lipid-rich cells. Cooling is also believed to induce lipolysis (e.g., fat metabolism) of lipid-rich cells to further enhance the reduction in subcutaneous lipid-rich cells. Vasoconstriction by means other than cooling are contemplated by the present invention. For example, pressure or administration of certain drugs may be employed to cause ischemia.


The coupling agent may be applied to the skin or to the interface member to provide improved thermal conductivity. The coupling agent may include polypropylene glycol, polyethylene glycol, propylene glycol, and/or glycol. Glycols, glycerols, and other deicing chemicals are efficient freezing-point depressants and act as a solute to lower the freezing point of the coupling agent. Propylene glycol is one exemplary component of deicer or non-freezing coupling agents. Other components include polypropylene glycol (PPG), polyethylene glycol (PEG), polyglycols, glycols, ethylene glycol, dimethyl sulfoxide, polyvinyl pyridine, calcium magnesium acetate, sodium acetate, ethanol and/or sodium formate. The coupling agent preferably has a freezing point in the range of −40° C. to 0° C., more preferably below −10° C. as further described in U.S. Provisional Application 60/795,799, entitled Coupling Agent For Use With a Cooling Device For Improved Removal of Heat From Subcutaneous Lipid-Rich Cells, filed on Apr. 28, 2006, herein incorporated in its entirety by reference.



FIG. 10 is a functional diagram showing exemplary software modules 940 suitable for use in the processing unit 114. Each component can be a computer program, procedure, or process written as source code in a conventional programming language, such as the C programming language, and can be presented for execution by the CPU of processor 942. The various implementations of the source code and object code can be stored on a computer-readable storage medium or embodied on a transmission medium in a carrier wave. The modules of processor 942 can include an input module 944, a database module 946, a process module 948, an output module 950, and, optionally, a display module 951. In another embodiment, the software modules 940 can be presented for execution by the CPU of a network server in a distributed computing scheme.


In operation, the input module 944 accepts an operator input, such as process setpoint and control selections, and communicates the accepted information or selections to other components for further processing. The database module 946 organizes records, including operating parameters 954, operator activities 956, and alarms 958, and facilitates storing and retrieving of these records to and from a database 952. Any type of database organization can be utilized, including a flat file system, hierarchical database, relational database, or distributed database, such as provided by a database vendor such as Oracle Corporation, Redwood Shores, Calif.


The process module 948 generates control variables based on sensor readings 960, and the output module 950 generates output signals 962 based on the control variables. For example, the output module 950 can convert the generated control variables from the process module 948 into 4-20 mA output signals 962 suitable for a direct current voltage modulator. The processor 942 optionally can include the display module 951 for displaying, printing, or downloading the sensor readings 960 and output signals 962 via devices such as the output device 120. A suitable display module 951 can be a video driver that enables the processor 942 to display the sensor readings 960 on the output device 120.


One interesting feature of a thermoelectric cooler is that if the polarity of the applied voltage is reversed, the cold side becomes warm and the warm side becomes cold. In this way, the thermoelectric cooler may be employed to increase the blood flow rate and stimulate reperfusion in the cooled tissue. This would cause ischemia-reperfusion injury and improve the results achieved by the methods described in U.S. Patent Publication No. 2003/0220674 and in U.S. Patent Publication No. 2005/0251120.


Regardless of the cooling element type, the cooling element can be maintained at an average temperature between about −30° C. and about 35° C., preferably from about −20° C. to about 20° C., more preferably from about −20° C. to about 10° C., more preferably from about −15° C. to about 5° C., more preferably from about −10° C. to about 0° C. In one embodiment, the region is exposed to the cooling element from about 2 min to about 60 min, or preferably from about 5 min to about 30 min.


After cooling has been effected or vasoconstriction otherwise induced, the tissue of interest is exposed to an energy source to increase blood flow. The term “energy source” refers to any known form of energy that would increase blood flow in a subject, either by inflammation or other mechanisms. As will be recognized, the energy source can be the same device used to effect cooling (as, for example, by changing the temperature profile of a fluid bath or by reversing polarity on the applied voltage of a thermoelectric cooler) or a different device. Energy sources according to the invention can supply electromagnetic energy (e.g., light, radiofrequency), thermal energy (e.g., heat) and/or mechanical energy (e.g., physical contact, friction, vibration, sound waves). In preferred embodiments, the energy source causes the blood flow rate to increase more rapidly than would occur without the energy source.


The energy source can, for example, be a capacitively coupled RF device such as those in which a power source provides energy to an RF generator and then to at least one RF electrode. An electronic measuring system measures current, voltage, and temperature via thermal sensors. The present invention utilizes an electronic measuring system driven by a controller, such as a computer with appropriate software. Various feedback or monitoring systems attached to the controller include ultrasonic, thermal, or impedance monitors. Current and voltage are used to calculate impedance. The output for these monitors is used by the controller to control the delivery of RF power. The amount of RF energy delivered controls the amount of RF power.


In one embodiment, the RF energy is provided by an RF electrode coated with dielectric material. The use of dielectric coating produces a more uniform impedance throughout the electrode and causes a more uniform current to flow through the electrode. The resulting effect minimizes edge effects around the edges of the electrode. It is desirable to have the electrical impedance of the dielectric layer to be higher than that of the subject tissue. In various embodiments, the impedance of layer 32′ at the operating frequency, can be in the range of 200 Ω/cm2 or greater. Suitable materials for a dielectric coating include, but are not limited to, TEFLON, silicon nitride, polysilanes, polysilazanes, polyimides, KAPTON, antenna dielectrics and other dielectric materials well known in the art.


In one embodiment, one or more RF electrodes are connected to an RF generator. The temperature of the tissue or of RF electrode is monitored, and the output power of energy source adjusted accordingly. The system can be a closed- or open-loop system to switch power on and off, as well as modulate the power. A closed-loop system utilizes a microprocessor to serve as a controller to monitor the temperature, adjust the RF power, analyze the result, feed back the result, and then modulate the power. More specifically, a controller governs the power levels, cycles, and duration that the radiofrequency energy is distributed to the individual electrodes to achieve and maintain power levels appropriate to achieve the desired treatment. In one embodiment, the controller is an INTEL PENTIUM microprocessor; however it will be appreciated that any suitable microprocessor or general purpose digital or analog computer can be used to perform one or more of the functions of controller.


With the use of sensor and feedback control system skin or other tissue adjacent to the RF electrode can be maintained at a desired temperature for a selected period of time without causing a shut-down of the power circuit to electrode due to the development of excessive electrical impedance at electrode or adjacent tissue. Current and voltage can be measured by sensors, and used to calculate impedance and power. A control signal is generated by controller that is proportional to the difference between an actual measured value, and a desired value. The control signal is used by power circuits to adjust the power output in an appropriate amount in order to maintain the desired power delivered at respective RF electrodes.


In a similar manner, temperatures detected at a sensor provide feedback for maintaining a selected power. A control signal is generated by a controller that is proportional to the difference between an actual measured temperature and a desired temperature. The control signal is used by power circuits to adjust the power output in an appropriate amount in order to maintain the desired temperature delivered at the sensor.


Examples of methods utilizing RF on a subject are disclosed in U.S. Pat. Nos. 6,413,255 and 5,948,011, the entire disclosures of which are incorporated herein.


Alternatively, the energy source can be vibrational, and delivered by a conventional vibrating device. Such vibratory massagers are known to increase blood circulation and perfusion. Representative devices include the Endermologie ES1 device (LPG Systems, Valence, France), VelaSmooth system (Syneron Inc, Richmond Hill, Ontario, Canada), and TriActive Laserdermology system (Cynosure Inc, Chelmsford, Mass., USA).


Alternatively, the energy source can be acoustic, and delivered by ultrasound transducers. Ultrasound energy is well known to those skilled in the art to be capable of heating tissue. Treatment devices can include a high intensity focused ultrasound (HIFU) system—in particular, a system with a plurality of independently controlled multiple beam transducer elements that are capable of being focused at the treatment depths below the skin surface. A HIFU transducer comprises an army of transducer elements. Each transducer element comprises a piezoelectric element, solid coupling element, and focusing lens. The transducer elements may span treatment depths including 0.35 to 3.5 cm. For example, five transducer elements may have focal points of 0.5, 0.8, 1.2, 1.9, and 3.0 cm, with correspondingly operate frequencies of 12, 9, 7, 5.5, and 4 MHz, respectively. It should be noted that the transducer may comprise different numbers of transducer elements.


The HIFU transducer supplies a predetermined amount of ultrasonic energy per unit distance traveled (not per unit time) for each treatment region and sensors that detect cavitation and boiling of the fat tissue. The HIFU transducer can be controlled to determine the desired temperature through feedback mechanisms. For example, a monitored Doppler dynamic sound caused by cavitation or boiling may be used as an indicator to set a power level outputted by the transducer in the HIFU system. Examples of methods utilizing HIFU on a subject are disclosed in U.S. Patent Publication No. 2006/0122509, U.S. Patent Publication No. 2005/0154431, and U.S. Patent Publication No. 2004/0039312, the entire disclosures of which are incorporated herein.


In one embodiment, the energy source is applied such that the region is warmed to about normal body temperature. Alternatively, the energy source is applied such that the region is warmed to above normal body temperature. Alternatively, the energy source is applied such that the region is warmed to a temperature warmer than the temperature of the previously cooled lipid-rich cells, at least enough to stimulate reperfusion.


The amount of time that the energy source is applied typically depends on the energy source itself. For example, depending on the source, the energy is applied for from about 1 sec to about 30 min. Preferably, the energy is applied for from about 1 sec to about 15 min. Skilled artisans are aware of the variables to consider when applying energy to a subject.


In certain embodiments, energy, such as capacitively coupled radiofrequency energy, is applied to the tissue with energy of about 10 J/cm2 to about 1000 J/cm2 is applied to the tissue. Preferably, about 50 J/cm2 to about 300 J/cm2 is applied to the tissue.


Free radical-mediated mechanisms of cellular damage are believed to be involved after periods of ischemia and reperfusion. Nishikawa, Ultrastructural Changes and Lipid Peroxidation in Rat Adipomusculocutaneous Flap Isotransplants after Normothermic Storage and Reperfusion, Transplantation, Vol. 54, 795-801, 1992. More particularly, it is known that fat has a greater predisposition to free radical damage than skin. Id; Coban, Ischemia-Reperfusion Injury of Adipofascial Tissue: An Experimental Study Evaluating Early Histologic and Biochemical Alterations in Rats, Mediators of Inflammation, Vol. 5, 304-308, 2005 (fat tissue is more susceptible to ischemic events). These studies look to minimize injury to fat tissue during transplants. By contrast, while not intending to be bound by theory, it is believed that it is beneficial to augment ischemia-reperfusion injury in the adipose tissue, thus enhancing adipose tissue necrosis.


The damage of reperfusion injury is due in part to the inflammatory response of damaged tissues. White blood cells carried to the area by the newly returning blood release a host of inflammatory factors such as interleukins as well as free radicals in response to tissue damage. The restored blood flow reintroduces oxygen within cells that damages cellular proteins, DNA, and the plasma membrane. Damage to the cell's membrane may in turn cause the release of more free radicals. Such reactive species may also act indirectly in redox signaling to turn on apoptosis. Redox signaling is the concept that free radicals, reactive oxygen species (ROS), and other electronically-activated species act as messengers in biological systems. Leukocytes may also build up in small capillaries, obstructing them and leading to more ischemia.


In certain embodiments, the methods of the invention further comprise treating the region to encourage formation of oxygen radicals. Oxygen radicals are damaging to tissues, and their concentration may be increased in a number of ways, including locally administering oxygen radical forming compounds (such as bleomycin) and compounds (such as the interleukins and other immune adjuvants) that stimulate inflammation by, for example, stimulating release of inflammatory mediators and/or leukocyte activity. In yet another embodiment, the method further comprises treating the region to encourage formation of intracellular and/or extracellular ion concentrations at other than normal levels.


The present invention provides methods of treating subcutaneous adipose tissue in a region of a subject's body, comprising exposing said region to a cooling element under conditions effective to cool said tissue; and stimulating reperfusion in the cooled tissue by exposing the tissue to an energy source to increase the blood flow rate to the cooled tissue. In one embodiment, stimulating reperfusion in the tissue causes ischemia-reperfusion injury to the tissue. Ischemia-reperfusion injury in the tissue permanently damages adipocytes present in the tissue.


In some embodiments, the methods further comprise determining the amount of adipocytes present in the tissue. The determination may be made before the exposing step, after the exposing step, or both before and after the exposing step.


In another embodiment, the present invention provides methods of treating subcutaneous adipose tissue in a region of a subject's body, comprising exposing said region to a cooling element under conditions effective to cool said tissue; and causing an ischemia-reperfusion injury to the cooled tissue by exposing the tissue to an energy source to increase the blood flow rate to the cooled tissue.


In the foregoing specification, the concepts have been described with reference to specific embodiments. Many aspects and embodiments have been described above and are merely exemplary and not limiting. After reading this specification, skilled artisans appreciate that other aspects and embodiments are possible without departing from the scope of the invention. Moreover, one of ordinary skill in the art appreciates that various modifications and changes can be made without departing from the scope of the invention as set forth in the claims below. Accordingly, the specification and figures are to be regarded in an illustrative rather than a restrictive sense, and all such modifications are intended to be included within the scope of invention.


Benefits, other advantages, and solutions to problems have been described above with regard to specific embodiments. However, the benefits, advantages, solutions to problems, and any feature(s) that may cause the same to occur or become more pronounced are not to be construed as a critical, required, or essential feature of any or all the claims.


It is to be appreciated that certain features are, for clarity, described herein in the context of separate embodiments, but may also be provided in combination in a single embodiment. Conversely, various features that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any subcombination. Further, reference to values stated in ranges include each and every value within that range.

Claims
  • 1. A method for affecting subcutaneous lipid-rich cells in a region of a human subject's body, the method comprising: (a) applying a heat exchanging surface of an applicator to the subject's skin;(b) cooling the region for at least 2 minutes using the heat exchanging surface that is at a temperature about −10° C. to about 0° C.;(c) after (b), reversing a polarity of energy applied to a thermoelectric element of the applicator, and, after reversing the polarity, and(d) causing an ischemia-reperfusion injury in the region by warming the heat exchanging surface so as to conductively heat the region for about 1 second to about 15 minutes using the warmed heat exchanging surface such that the previously cooled region is warmed to either a normal body temperature or higher temperature in less than or about 15 minutes thereby to cause damage to the subcutaneous lipid-rich cells.
  • 2. The method of claim 1, wherein conductively heating the region includes warming cooled subcutaneous lipid-rich cells in the region to enhance disruption of the subcutaneous lipid-rich cells.
  • 3. The method of claim 1, wherein conductively heating the region includes heating cooled subcutaneous lipid-rich cells at the region at a heating rate sufficiently high to injure the subcutaneous lipid-rich cells.
  • 4. The method of claim 1, wherein conductively heating the region includes warming the region to a temperature above normal body temperature to affect subcutaneous lipid-rich cells.
  • 5. The method of claim 1, further comprising cycling at least one of (b) and (c).
  • 6. The method of claim 1, further comprising cooling the region using the heat exchanging surface that is at a temperature from about −20° C. to about 10° C. such that the region is at temperature from about −20° C. to about 10° C. for at least 5 minutes.
  • 7. The method of claim 1, wherein the applicator includes a temperature control element in thermal communication with the heat exchanging surface, and wherein the temperature control element includes a thermoelectric element configured to be actively heated and cooled using a liquid.
  • 8. The method of claim 7, wherein the heat exchanging surface is heated and cooled by the thermoelectric element by reversing a polarity of an applied voltage on the thermoelectric element.
  • 9. The method of claim 1, further comprising using the heat exchanging surface to cool the region to a temperature less than about −2° C.
  • 10. The method of claim 1, further comprising using the heat exchanging surface to cool the region to a temperature less than −2° C. prior to producing the non-freeze injury.
  • 11. The method of claim 1, wherein the ischemia-reperfusion injury includes excessive heating that causes destruction of the subcutaneous tissue.
  • 12. A method for selective reduction of lipid-rich cells in a region of a human subject's body, comprising: exposing an epidermal layer in the region to an element that is cooled and substantially stationary relative to the region and at a temperature lower than −5° C. for at least 5 minutes to cool the skin to a temperature lower than −5° C. and subcutaneous lipid-rich cells in the region of the subject to a temperature lower than −2° C. to selectively disrupt lipid-rich cells in the region;exposing tissue cooled by the element to energy from an energy source positioned external to the subject, the energy source is capable of operating independently of the element to increase a rate of blood flow to the cooled tissue and/or to increase a temperature of the cooled tissue to at least normal body temperature in less than or about 15 minutes to cause ischemia-reperfusion injury to permanently damage a sufficient amount of subcutaneous lipid-rich cells to substantially reduce the number of lipid-rich cells in the region, wherein the energy includes one or more of thermal energy, acoustic energy, and electromagnetic energy.
  • 13. The method of claim 12 wherein exposing the cooled tissue to energy includes delivering radiofrequency energy from the energy source to the cooled tissue.
  • 14. The method of claim 12 wherein exposing the cooled tissue to energy includes delivering light from the energy source to the cooled tissue.
  • 15. The method of claim 12 wherein exposing the cooled tissue to energy includes: capacitively coupling the energy source to the subject; anddelivering capacitively coupled radiofrequency energy to the subject.
  • 16. The method of claim 12 wherein exposing the cooled tissue to the energy includes delivering the energy from the energy source while the energy source is spaced apart from the subject.
  • 17. The method of claim 16, further comprising applying coupling gel to the subject's skin and/or the energy source before delivering the energy from the energy source to the subject.
  • 18. The method of claim 12 wherein exposing the cooled tissue to energy includes delivering ultrasound energy from the energy source to the cooled tissue.
  • 19. The method of claim 12 wherein exposing the issue to energy from the energy source includes applying radiofrequency energy at an energy level of about 10 J/cm2 to about 1000 J/cm2.
  • 20. The method of 12 wherein exposing the tissue to energy from the energy source includes applying radiofrequency energy at an energy level of about 50 J/cm2 to about 300 J/cm2.
  • 21. A method for reducing subcutaneous lipid-rich cells in subcutaneous tissue in a region of a human subject's body, the method comprising: applying an applicator with a heat exchanging surface to the region and applying energy to the heat exchanging surface;cooling the region using the heat exchanging surface at a temperature in a range from about −10° C. to about 0° C. and for a cooling period longer than about 5 minutes such that subcutaneous lipid-rich cells in the subcutaneous tissue of the region are selectively disrupted while inhibiting damage to the subject's epiderm is;after the cooling period, reversing a polarity of energy applied to the heat exchanging surface, and after reversing the polarity of energy, andcausing an ischemia-reperfusion injury to the subcutaneous tissue by conductively heating the previously cooled tissue at the region using the heat exchanging surface after the cooling period to increase the temperature of the previously cooled tissue to at least normal body temperature in less than or about 15 minutes thereby damaging the subcutaneous lipid-rich cells in the subcutaneous tissue.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 13/471,826, filed May 15, 2012, which is a continuation of U.S. patent application Ser. No. 14/558,046, filed Nov. 9, 2006, now U.S. Pat. No. 8,192,474. Each of these applications is incorporated herein by reference in its entirety.

US Referenced Citations (704)
Number Name Date Kind
681806 Mignault et al. Sep 1901 A
889810 Robinson et al. Jun 1908 A
1093868 Leighty Apr 1914 A
2516491 Swastek Jul 1950 A
2521780 Dodd et al. Sep 1950 A
2726658 Chessey Dec 1955 A
2766619 Tribus et al. Oct 1956 A
2851602 Cramwinckel et al. Sep 1958 A
3093135 Hirschhorn Jun 1963 A
3132688 Nowak May 1964 A
3133539 Eidus et al. May 1964 A
3282267 Eidus Nov 1966 A
3341230 Louis Sep 1967 A
3502080 Hirschhorn Mar 1970 A
3566871 Richter et al. Mar 1971 A
3587577 Zubkov et al. Jun 1971 A
3591645 Selwitz Jul 1971 A
3692338 Nick Sep 1972 A
3703897 Mack et al. Nov 1972 A
3710784 Taylor Jan 1973 A
3786814 Armao Jan 1974 A
3827436 Andera et al. Aug 1974 A
3942519 Shock Mar 1976 A
3948269 Zimmer Apr 1976 A
3986385 Johnston et al. Oct 1976 A
3993053 Grossan Nov 1976 A
4002221 Buchalter Jan 1977 A
4008910 Roche Feb 1977 A
4026299 Sauder May 1977 A
4140130 Storm Feb 1979 A
4149529 Copeland et al. Apr 1979 A
4178429 Scheffer Dec 1979 A
4202336 van Gerven May 1980 A
4266043 Fujii et al. May 1981 A
4269068 Molina May 1981 A
4381009 Del Bon Apr 1983 A
4396011 Mack et al. Aug 1983 A
4459854 Richardson et al. Jul 1984 A
4470263 Lehovec et al. Sep 1984 A
4483341 Les Nov 1984 A
4528979 Marchenko et al. Jul 1985 A
4531524 Mioduski Jul 1985 A
4548212 Leung Oct 1985 A
4555313 Duchane et al. Nov 1985 A
4585002 Kissin Apr 1986 A
4603076 Bowditch et al. Jul 1986 A
4614191 Perler et al. Sep 1986 A
4644955 Mioduski Feb 1987 A
4664110 Schanzlin May 1987 A
4700701 Montaldi Oct 1987 A
4718429 Smidt Jan 1988 A
4741338 Miyamae May 1988 A
4758217 Gueret Jul 1988 A
4764463 Mason et al. Aug 1988 A
4802475 Weshahy Feb 1989 A
4832022 Tjulkov et al. May 1989 A
4846176 Golden Jul 1989 A
4850340 Onishi Jul 1989 A
4869250 Bitterly Sep 1989 A
4880564 Abel et al. Nov 1989 A
4905697 Heggs et al. Mar 1990 A
4906463 Cleary et al. Mar 1990 A
4930317 Klein Jun 1990 A
4935345 Guilbeau et al. Jun 1990 A
4961422 Marchosky et al. Oct 1990 A
4962761 Golden Oct 1990 A
4990144 Blott et al. Feb 1991 A
5007433 Hermsdoerffer et al. Apr 1991 A
5018521 Campbell et al. May 1991 A
5024650 Hagiwara et al. Jun 1991 A
5065752 Sessions et al. Nov 1991 A
5069208 Noppel et al. Dec 1991 A
5084671 Miyata et al. Jan 1992 A
5108390 Potocky et al. Apr 1992 A
5119674 Nielsen Jun 1992 A
5139496 Hed et al. Aug 1992 A
5143063 Fellner Sep 1992 A
5148804 Hill et al. Sep 1992 A
5158070 Dory Oct 1992 A
5160312 Voelkel Nov 1992 A
5169384 Bosniak et al. Dec 1992 A
5197466 Marchosky et al. Mar 1993 A
5207674 Hamilton May 1993 A
5209227 Deutsch May 1993 A
5221726 Dabi et al. Jun 1993 A
5264234 Windhab et al. Nov 1993 A
5277030 Miller Jan 1994 A
5314423 Seney et al. May 1994 A
5327886 Chiu Jul 1994 A
5330745 Mcdow et al. Jul 1994 A
5333460 Lewis et al. Aug 1994 A
5334131 Omandam et al. Aug 1994 A
5336616 Livesey et al. Aug 1994 A
5339541 Owens Aug 1994 A
5342617 Gold et al. Aug 1994 A
5351677 Kami et al. Oct 1994 A
5358467 Milstein et al. Oct 1994 A
5362966 Rosenthal et al. Nov 1994 A
5363347 Nguyen Nov 1994 A
5372608 Johnson Dec 1994 A
5386837 Sterzer Feb 1995 A
5411541 Bell et al. May 1995 A
5427772 Hagan et al. Jun 1995 A
5433717 Rubinsky et al. Jul 1995 A
5456703 Beeuwkes, III et al. Oct 1995 A
5472416 Blugerman et al. Dec 1995 A
5486207 Mahawili Jan 1996 A
5497596 Zatkulak Mar 1996 A
5501655 Rolt et al. Mar 1996 A
5505726 Meserol Apr 1996 A
5505730 Edwards et al. Apr 1996 A
5507790 Weiss Apr 1996 A
5514105 Goodman, Jr. et al. May 1996 A
5514170 Mauch May 1996 A
5516505 Mcdow May 1996 A
5531742 Barken Jul 1996 A
5558376 Woehl Sep 1996 A
5562604 Yablon et al. Oct 1996 A
5571801 Segall et al. Nov 1996 A
5575812 Owens et al. Nov 1996 A
5603221 Maytal Feb 1997 A
5628769 Saringer May 1997 A
5634890 Morris Jun 1997 A
5634940 Panyard Jun 1997 A
5647051 Neer Jul 1997 A
5647868 Chinn Jul 1997 A
5650450 Lovette et al. Jul 1997 A
5651773 Perry et al. Jul 1997 A
5654279 Rubinsky et al. Aug 1997 A
5654546 Lindsay et al. Aug 1997 A
5660836 Knowlton et al. Aug 1997 A
5665053 Jacobs Sep 1997 A
5672172 Zupkas Sep 1997 A
5700284 Owens et al. Dec 1997 A
5725483 Podolsky Mar 1998 A
5733280 Avitall Mar 1998 A
5741248 Stern et al. Apr 1998 A
5746702 Gelfgat et al. May 1998 A
5746736 Tankovich May 1998 A
5755663 Larsen et al. May 1998 A
5755753 Knowlton et al. May 1998 A
5755755 Panyard May 1998 A
5759182 Varney et al. Jun 1998 A
5759764 Polovina et al. Jun 1998 A
5769879 Richards et al. Jun 1998 A
5785955 Fischer Jul 1998 A
5792080 Ookawa et al. Aug 1998 A
5800490 Patz et al. Sep 1998 A
5802865 Strauss Sep 1998 A
5814040 Nelson et al. Sep 1998 A
5817050 Klein et al. Oct 1998 A
5817149 Owens et al. Oct 1998 A
5817150 Owens et al. Oct 1998 A
5830208 Muller Nov 1998 A
5833685 Tortal et al. Nov 1998 A
5844013 Kenndoff et al. Dec 1998 A
5853364 Baker et al. Dec 1998 A
5865841 Kolen et al. Feb 1999 A
5871524 Knowlton Feb 1999 A
5871526 Gibbs et al. Feb 1999 A
5885211 Eppstein et al. Mar 1999 A
5891617 Watson et al. Apr 1999 A
5895418 Saringer Apr 1999 A
5901707 Goncalves May 1999 A
5902256 Benaron May 1999 A
5919219 Knowlton et al. Jul 1999 A
5944748 Mager et al. Aug 1999 A
5948011 Knowlton et al. Sep 1999 A
5954680 Augustine et al. Sep 1999 A
5964092 Tozuka et al. Oct 1999 A
5964749 Eckhouse et al. Oct 1999 A
5967976 Larsen et al. Oct 1999 A
5980561 Kolen et al. Nov 1999 A
5986167 Arteman et al. Nov 1999 A
5989286 Owens et al. Nov 1999 A
5997530 Nelson et al. Dec 1999 A
6017337 Pira Jan 2000 A
6023932 Johnston Feb 2000 A
6032675 Rubinsky Mar 2000 A
6039694 Larson et al. Mar 2000 A
6041787 Rubinsky Mar 2000 A
6047215 McClure et al. Apr 2000 A
6049927 Thomas et al. Apr 2000 A
6051159 Hao et al. Apr 2000 A
6071239 Cribbs et al. Jun 2000 A
6074415 Der Ovanesian Jun 2000 A
6093230 Johnson et al. Jul 2000 A
6102885 Bass Aug 2000 A
6104952 Tu et al. Aug 2000 A
6104959 Spertell et al. Aug 2000 A
6106517 Zupkas Aug 2000 A
6113558 Rosenschein et al. Sep 2000 A
6113559 Klopotek Sep 2000 A
6113626 Clifton et al. Sep 2000 A
6120519 Weber et al. Sep 2000 A
6139544 Mikus et al. Oct 2000 A
6150148 Nanda et al. Nov 2000 A
6151735 Koby et al. Nov 2000 A
6152952 Owens et al. Nov 2000 A
6171301 Nelson et al. Jan 2001 B1
6180867 Hedengren et al. Jan 2001 B1
6226996 Weber et al. May 2001 B1
6241753 Knowlton Jun 2001 B1
6264649 Whitcroft et al. Jul 2001 B1
6273884 Altshuler et al. Aug 2001 B1
6290988 Van Vilsteren et al. Sep 2001 B1
6311090 Knowlton Oct 2001 B1
6311497 Chung Nov 2001 B1
6312453 Stefanile et al. Nov 2001 B1
6350276 Knowlton Feb 2002 B1
6354297 Eiseman Mar 2002 B1
6357907 Cleveland et al. Mar 2002 B1
6375673 Clifton et al. Apr 2002 B1
6377854 Knowlton Apr 2002 B1
6377855 Knowlton Apr 2002 B1
6381497 Knowlton Apr 2002 B1
6381498 Knowlton Apr 2002 B1
6387380 Knowlton May 2002 B1
6401722 Krag Jun 2002 B1
6405090 Knowlton Jun 2002 B1
6413255 Stern Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6426445 Young et al. Jul 2002 B1
6430446 Knowlton Aug 2002 B1
6430956 Haas et al. Aug 2002 B1
6438424 Knowlton Aug 2002 B1
6438954 Goetz et al. Aug 2002 B1
6438964 Giblin Aug 2002 B1
6453202 Knowlton Sep 2002 B1
6458888 Hood et al. Oct 2002 B1
6461378 Knowlton Oct 2002 B1
6470216 Knowlton Oct 2002 B1
6471693 Carroll et al. Oct 2002 B1
6475211 Chess et al. Nov 2002 B2
6478811 Dobak, III et al. Nov 2002 B1
6494844 Van Bladel et al. Dec 2002 B1
6497721 Ginsburg et al. Dec 2002 B2
6508831 Kushnir Jan 2003 B1
6514244 Pope et al. Feb 2003 B2
6519964 Bieberich Feb 2003 B2
6523354 Tolbert Feb 2003 B1
6527765 Kelman et al. Mar 2003 B2
6527798 Ginsburg et al. Mar 2003 B2
6544248 Bass Apr 2003 B1
6547811 Becker et al. Apr 2003 B1
6548297 Kuri-Harcuch et al. Apr 2003 B1
6551255 Van Bladel et al. Apr 2003 B2
6551341 Boylan et al. Apr 2003 B2
6551348 Blalock et al. Apr 2003 B1
6551349 Lasheras et al. Apr 2003 B2
6569189 Augustine et al. May 2003 B1
6585652 Lang et al. Jul 2003 B2
6592577 Abboud et al. Jul 2003 B2
6605080 Altshuler et al. Aug 2003 B1
6607498 Eshel Aug 2003 B2
6620187 Carson et al. Sep 2003 B2
6620188 Ginsburg et al. Sep 2003 B1
6620189 Machold et al. Sep 2003 B1
6623430 Slayton et al. Sep 2003 B1
6626854 Friedman et al. Sep 2003 B2
6632219 Baranov et al. Oct 2003 B1
6635053 Lalonde et al. Oct 2003 B1
6643535 Damasco et al. Nov 2003 B2
6645162 Friedman et al. Nov 2003 B2
6645229 Matsumura et al. Nov 2003 B2
6645232 Carson Nov 2003 B2
6648904 Altshuler et al. Nov 2003 B2
6656208 Grahn et al. Dec 2003 B2
6660027 Gruszecki et al. Dec 2003 B2
6662054 Kreindel et al. Dec 2003 B2
6682550 Clifton et al. Jan 2004 B2
6685731 Kushnir et al. Feb 2004 B2
6694170 Mikus et al. Feb 2004 B1
6695874 Machold et al. Feb 2004 B2
6697670 Chornenky Feb 2004 B2
6699237 Weber et al. Mar 2004 B2
6699266 Lachenbruch et al. Mar 2004 B2
6699267 Voorhees et al. Mar 2004 B2
6718785 Bieberich Apr 2004 B2
6741895 Gafni et al. May 2004 B1
6743222 Durkin et al. Jun 2004 B2
6746474 Saadat Jun 2004 B2
6749624 Knowlton Jun 2004 B2
6753182 Kadkade et al. Jun 2004 B1
6764493 Weber et al. Jul 2004 B1
6764502 Bieberich Jul 2004 B2
6789545 Littrup et al. Sep 2004 B2
6795728 Chornenky et al. Sep 2004 B2
6820961 Johnson Nov 2004 B2
6821274 McHale et al. Nov 2004 B2
6840955 Ein Jan 2005 B2
6849075 Bertolero et al. Feb 2005 B2
6878144 Altshuler et al. Apr 2005 B2
6889090 Kreindel May 2005 B2
6892099 Jaafar et al. May 2005 B2
6904956 Noel Jun 2005 B2
6918903 Bass Jul 2005 B2
6927316 Fades, Jr. et al. Aug 2005 B1
6942022 Blangetti et al. Sep 2005 B2
6945942 Van Bladel et al. Sep 2005 B2
6948903 Ablabutyan et al. Sep 2005 B2
6969399 Schock et al. Nov 2005 B2
7005558 Johansson et al. Feb 2006 B1
7006874 Knowlton et al. Feb 2006 B2
7022121 Stern et al. Apr 2006 B2
7037326 Lee May 2006 B2
7054685 Dimmer et al. May 2006 B2
7060061 Altshuler et al. Jun 2006 B2
7077858 Fletcher et al. Jul 2006 B2
7081111 Svaasand et al. Jul 2006 B2
7083612 Littrup et al. Aug 2006 B2
7096204 Chen et al. Aug 2006 B1
7112712 Ancell Sep 2006 B1
7115123 Knowlton et al. Oct 2006 B2
7141049 Stern et al. Nov 2006 B2
7183360 Daniel et al. Feb 2007 B2
7189252 Krueger Mar 2007 B2
7192426 Baust et al. Mar 2007 B2
7204832 Altshuler et al. Apr 2007 B2
7220778 Anderson et al. May 2007 B2
7229436 Stern et al. Jun 2007 B2
7258674 Cribbs et al. Aug 2007 B2
7267675 Stern et al. Sep 2007 B2
7276058 Altshuler et al. Oct 2007 B2
7318821 Lalonde et al. Jan 2008 B2
7331951 Eshel et al. Feb 2008 B2
7347855 Eshel et al. Mar 2008 B2
7367341 Anderson et al. May 2008 B2
7532201 Quistgaard et al. May 2009 B2
7572268 Babaev Aug 2009 B2
7604632 Howlett et al. Oct 2009 B2
7613523 Eggers et al. Nov 2009 B2
7615016 Barthe et al. Nov 2009 B2
7713266 Elkins et al. May 2010 B2
7780656 Tankovich Aug 2010 B2
7799018 Goulko Sep 2010 B2
7824437 Saunders Nov 2010 B1
7828831 Tanhehco et al. Nov 2010 B1
7850683 Elkins et al. Dec 2010 B2
7854754 Ting et al. Dec 2010 B2
7862558 Elkins et al. Jan 2011 B2
RE42277 Jaafar et al. Apr 2011 E
7938824 Chornenky et al. May 2011 B2
7959657 Harsy et al. Jun 2011 B1
7963959 Da Silva et al. Jun 2011 B2
7967763 Deem et al. Jun 2011 B2
7993330 Goulko Aug 2011 B2
7998137 Elkins et al. Aug 2011 B2
RE42835 Chornenky et al. Oct 2011 E
RE43009 Chornenky et al. Dec 2011 E
8133180 Slayton et al. Mar 2012 B2
8133191 Rosenberg et al. Mar 2012 B2
8192474 Levinson Jun 2012 B2
8246611 Paithankar et al. Aug 2012 B2
8275442 Allison Sep 2012 B2
8285390 Levinson et al. Oct 2012 B2
8333700 Barthe et al. Dec 2012 B1
8337539 Ting et al. Dec 2012 B2
8366622 Slayton et al. Feb 2013 B2
8372130 Young et al. Feb 2013 B2
8397518 Vistakula et al. Mar 2013 B1
8414631 Quisenberry et al. Apr 2013 B2
8433400 Prushinskaya et al. Apr 2013 B2
8506486 Slayton et al. Aug 2013 B2
8523775 Barthe et al. Sep 2013 B2
8523791 Castel Sep 2013 B2
8523927 Levinson et al. Sep 2013 B2
8535228 Slayton et al. Sep 2013 B2
8603073 Allison Dec 2013 B2
8636665 Slayton et al. Jan 2014 B2
8641622 Barthe et al. Feb 2014 B2
8663112 Slayton et al. Mar 2014 B2
8672848 Slayton et al. Mar 2014 B2
8676332 Fahey Mar 2014 B2
8690778 Slayton et al. Apr 2014 B2
8690779 Slayton et al. Apr 2014 B2
8690780 Slayton et al. Apr 2014 B2
8702774 Baker et al. Apr 2014 B2
8758215 Legendre et al. Jun 2014 B2
8764693 Graham et al. Jul 2014 B1
8834547 Anderson et al. Sep 2014 B2
9149322 Knowlton Oct 2015 B2
20010005791 Ginsburg et al. Jun 2001 A1
20010007952 Shimizu Jul 2001 A1
20010023364 Ahn Sep 2001 A1
20010031459 Fahy et al. Oct 2001 A1
20010039439 Elkins et al. Nov 2001 A1
20010045104 Bailey, Sr. et al. Nov 2001 A1
20010047196 Ginsburg et al. Nov 2001 A1
20020026226 Ein Feb 2002 A1
20020032473 Kushnir et al. Mar 2002 A1
20020042607 Palmer et al. Apr 2002 A1
20020049483 Knowlton Apr 2002 A1
20020058975 Bieberich May 2002 A1
20020062142 Knowlton May 2002 A1
20020068338 Nanda et al. Jun 2002 A1
20020068874 Zuckerwar et al. Jun 2002 A1
20020082668 Man Jun 2002 A1
20020103520 Latham Aug 2002 A1
20020107558 Clifton et al. Aug 2002 A1
20020117293 Campbell Aug 2002 A1
20020120315 Furuno et al. Aug 2002 A1
20020128648 Weber et al. Sep 2002 A1
20020151830 Kahn Oct 2002 A1
20020151887 Stern et al. Oct 2002 A1
20020156509 Cheung Oct 2002 A1
20020188286 Quijano et al. Dec 2002 A1
20020198518 Mikus et al. Dec 2002 A1
20030032900 Ella Feb 2003 A1
20030044764 Soane et al. Mar 2003 A1
20030055414 Altshuler et al. Mar 2003 A1
20030062040 Lurie et al. Apr 2003 A1
20030069618 Smith, III et al. Apr 2003 A1
20030077326 Newton et al. Apr 2003 A1
20030077329 Kipp et al. Apr 2003 A1
20030079488 Bieberich May 2003 A1
20030100936 Altshuler et al. May 2003 A1
20030109908 Lachenbruch et al. Jun 2003 A1
20030109910 Lachenbruch et al. Jun 2003 A1
20030109911 Lachenbruch et al. Jun 2003 A1
20030109912 Joye et al. Jun 2003 A1
20030114885 Nova et al. Jun 2003 A1
20030120268 Bertolero et al. Jun 2003 A1
20030125649 McIntosh et al. Jul 2003 A1
20030187488 Kreindel et al. Oct 2003 A1
20030199226 Sommer et al. Oct 2003 A1
20030199859 Altshuler et al. Oct 2003 A1
20030220594 Halvorson et al. Nov 2003 A1
20030220635 Knowlton et al. Nov 2003 A1
20030220674 Anderson et al. Nov 2003 A1
20030236487 Knowlton Dec 2003 A1
20040002705 Knowlton et al. Jan 2004 A1
20040006328 Anderson Jan 2004 A1
20040009936 Tang et al. Jan 2004 A1
20040024437 Machold et al. Feb 2004 A1
20040030332 Knowlton et al. Feb 2004 A1
20040034341 Altshuler et al. Feb 2004 A1
20040039312 Hillstead Feb 2004 A1
20040044384 Leber et al. Mar 2004 A1
20040049178 Abboud et al. Mar 2004 A1
20040073079 Altshuler et al. Apr 2004 A1
20040074629 Noel Apr 2004 A1
20040077977 Ella et al. Apr 2004 A1
20040082886 Timpson Apr 2004 A1
20040093042 Altshuler et al. May 2004 A1
20040104012 Zhou et al. Jun 2004 A1
20040106867 Eshel et al. Jun 2004 A1
20040133251 Altshuler et al. Jul 2004 A1
20040162596 Altshuler et al. Aug 2004 A1
20040176667 Mihai et al. Sep 2004 A1
20040186535 Knowlton Sep 2004 A1
20040199226 Shadduck Oct 2004 A1
20040206365 Knowlton Oct 2004 A1
20040210214 Knowlton Oct 2004 A1
20040210287 Greene Oct 2004 A1
20040215294 Littrup et al. Oct 2004 A1
20040249427 Nabilsi et al. Dec 2004 A1
20040259855 Anderson et al. Dec 2004 A1
20040260209 Ella et al. Dec 2004 A1
20040260210 Ella et al. Dec 2004 A1
20040260211 Maalouf Dec 2004 A1
20040267339 Yon et al. Dec 2004 A1
20050010197 Lau et al. Jan 2005 A1
20050033957 Enokida Feb 2005 A1
20050049526 Baer Mar 2005 A1
20050049543 Anderson et al. Mar 2005 A1
20050049661 Koffroth Mar 2005 A1
20050113725 Masuda May 2005 A1
20050143781 Carbunaru et al. Jun 2005 A1
20050145372 Noel Jul 2005 A1
20050149153 Nakase et al. Jul 2005 A1
20050154314 Quistgaard Jul 2005 A1
20050154431 Quistgaard et al. Jul 2005 A1
20050159986 Breeland et al. Jul 2005 A1
20050177075 Meunier et al. Aug 2005 A1
20050182462 Chornenky et al. Aug 2005 A1
20050187495 Quistgaard et al. Aug 2005 A1
20050187597 Vanderschuit Aug 2005 A1
20050203446 Takashima Sep 2005 A1
20050215987 Slatkine Sep 2005 A1
20050222565 Manstein Oct 2005 A1
20050251117 Anderson et al. Nov 2005 A1
20050251120 Anderson et al. Nov 2005 A1
20050261753 Littrup et al. Nov 2005 A1
20050277859 Carlsmith et al. Dec 2005 A1
20050283144 Shiono et al. Dec 2005 A1
20060030778 Mendlein et al. Feb 2006 A1
20060035380 Saint-Leger Feb 2006 A1
20060036300 Kreindel Feb 2006 A1
20060041704 Choi Feb 2006 A1
20060074313 Slayton et al. Apr 2006 A1
20060079852 Bubb et al. Apr 2006 A1
20060094988 Tosaya et al. May 2006 A1
20060106836 Masugi et al. May 2006 A1
20060111613 Boutillette et al. May 2006 A1
20060122509 Desilets Jun 2006 A1
20060189964 Anderson et al. Aug 2006 A1
20060195168 Dunbar et al. Aug 2006 A1
20060200063 Munro et al. Sep 2006 A1
20060206040 Greenberg et al. Sep 2006 A1
20060206110 Knowlton et al. Sep 2006 A1
20060234899 Nekmard et al. Oct 2006 A1
20060259102 Slatkine Nov 2006 A1
20060265032 Hennings et al. Nov 2006 A1
20060270745 Hunt et al. Nov 2006 A1
20060293734 Scott et al. Dec 2006 A1
20070010811 Stern et al. Jan 2007 A1
20070010861 Anderson et al. Jan 2007 A1
20070032561 Lin et al. Feb 2007 A1
20070038156 Rosenberg Feb 2007 A1
20070055156 Desilets et al. Mar 2007 A1
20070055173 DeLonzor et al. Mar 2007 A1
20070055179 Deem et al. Mar 2007 A1
20070055180 Deem et al. Mar 2007 A1
20070055181 Deem et al. Mar 2007 A1
20070073367 Jones et al. Mar 2007 A1
20070078502 Weber et al. Apr 2007 A1
20070100398 Sloan May 2007 A1
20070106342 Schumann May 2007 A1
20070129714 Elkins Jun 2007 A1
20070135876 Weber Jun 2007 A1
20070141265 Thomson Jun 2007 A1
20070179482 Anderson et al. Aug 2007 A1
20070198071 Ting et al. Aug 2007 A1
20070219540 Masotti et al. Sep 2007 A1
20070239062 Chopra Oct 2007 A1
20070239075 Rosenberg et al. Oct 2007 A1
20070239150 Zvuloni et al. Oct 2007 A1
20070249519 Guha et al. Oct 2007 A1
20070255187 Branch Nov 2007 A1
20070255274 Stern et al. Nov 2007 A1
20070255362 Levinson et al. Nov 2007 A1
20070265585 Joshi et al. Nov 2007 A1
20070265614 Stern et al. Nov 2007 A1
20070270925 Levinson Nov 2007 A1
20070282249 Quisenberry et al. Dec 2007 A1
20070282318 Spooner et al. Dec 2007 A1
20080014627 Merchant et al. Jan 2008 A1
20080046047 Jacobs Feb 2008 A1
20080058784 Manstein et al. Mar 2008 A1
20080077201 Levinson et al. Mar 2008 A1
20080077202 Levinson Mar 2008 A1
20080077211 Levinson et al. Mar 2008 A1
20080097207 Cai et al. Apr 2008 A1
20080139901 Altshuler et al. Jun 2008 A1
20080140061 Toubia et al. Jun 2008 A1
20080140371 Warner Jun 2008 A1
20080161892 Mercuro et al. Jul 2008 A1
20080183164 Elkins et al. Jul 2008 A1
20080188915 Mills et al. Aug 2008 A1
20080248554 Merchant et al. Oct 2008 A1
20080269851 Deem et al. Oct 2008 A1
20080287839 Rosen et al. Nov 2008 A1
20080300529 Reinstein Dec 2008 A1
20080312651 Pope et al. Dec 2008 A1
20090012434 Anderson Jan 2009 A1
20090018623 Levinson et al. Jan 2009 A1
20090018624 Levinson et al. Jan 2009 A1
20090018625 Levinson et al. Jan 2009 A1
20090018626 Levinson et al. Jan 2009 A1
20090018627 Levinson et al. Jan 2009 A1
20090024023 Welches et al. Jan 2009 A1
20090076488 Welches et al. Mar 2009 A1
20090112134 Avni Apr 2009 A1
20090118722 Ebbers et al. May 2009 A1
20090149929 Levinson et al. Jun 2009 A1
20090149930 Schenck Jun 2009 A1
20090171253 Davenport Jul 2009 A1
20090171334 Elkins et al. Jul 2009 A1
20090221938 Rosenberg et al. Sep 2009 A1
20090226424 Hsu Sep 2009 A1
20090276018 Brader Nov 2009 A1
20090281464 Cioanta et al. Nov 2009 A1
20090299234 Cho et al. Dec 2009 A1
20090306749 Mulindwa Dec 2009 A1
20090312676 Rousso et al. Dec 2009 A1
20090312693 Thapliyal et al. Dec 2009 A1
20090326621 El-Galley Dec 2009 A1
20100015190 Hassler Jan 2010 A1
20100028969 Mueller et al. Feb 2010 A1
20100030306 Edelman et al. Feb 2010 A1
20100036295 Altshuler et al. Feb 2010 A1
20100042087 Goldboss et al. Feb 2010 A1
20100049178 Deem et al. Feb 2010 A1
20100081971 Allison Apr 2010 A1
20100087806 Da Silva et al. Apr 2010 A1
20100152824 Allison Jun 2010 A1
20100168726 Brookman Jul 2010 A1
20100179531 Nebrigic et al. Jul 2010 A1
20100198064 Perl et al. Aug 2010 A1
20100217349 Fahey et al. Aug 2010 A1
20100241023 Gilbert Sep 2010 A1
20100268220 Johnson et al. Oct 2010 A1
20100280582 Baker et al. Nov 2010 A1
20110009860 Chornenky et al. Jan 2011 A1
20110040235 Castel Feb 2011 A1
20110040299 Kim et al. Feb 2011 A1
20110046523 Altshuler et al. Feb 2011 A1
20110060323 Baust et al. Mar 2011 A1
20110066083 Tosaya et al. Mar 2011 A1
20110066216 Ting et al. Mar 2011 A1
20110077557 Wing et al. Mar 2011 A1
20110077723 Parish et al. Mar 2011 A1
20110112405 Barthe et al. May 2011 A1
20110112520 Kreindel May 2011 A1
20110144631 Elkins et al. Jun 2011 A1
20110152849 Baust et al. Jun 2011 A1
20110172651 Altshuler et al. Jul 2011 A1
20110189129 Qiu et al. Aug 2011 A1
20110196395 Maschke Aug 2011 A1
20110196438 Winozil et al. Aug 2011 A1
20110202048 Nebrigic et al. Aug 2011 A1
20110238050 Allison et al. Sep 2011 A1
20110238051 Levinson et al. Sep 2011 A1
20110257642 Griggs, III Oct 2011 A1
20110288537 Halaka Nov 2011 A1
20110300079 Martens et al. Dec 2011 A1
20110301585 Goulko Dec 2011 A1
20110313411 Anderson et al. Dec 2011 A1
20110313412 Kim et al. Dec 2011 A1
20120010609 Deem et al. Jan 2012 A1
20120016239 Barthe et al. Jan 2012 A1
20120022518 Levinson Jan 2012 A1
20120022622 Johnson et al. Jan 2012 A1
20120035475 Barthe et al. Feb 2012 A1
20120035476 Barthe et al. Feb 2012 A1
20120041525 Kami Feb 2012 A1
20120046547 Barthe et al. Feb 2012 A1
20120053458 Barthe et al. Mar 2012 A1
20120065629 Elkins et al. Mar 2012 A1
20120083862 Altshuler et al. Apr 2012 A1
20120101549 Schumann Apr 2012 A1
20120109041 Munz May 2012 A1
20120158100 Schomacker Jun 2012 A1
20120209363 Williams, III et al. Aug 2012 A1
20120233736 Tepper et al. Sep 2012 A1
20120239123 Weber et al. Sep 2012 A1
20120253416 Erez et al. Oct 2012 A1
20120259322 Fourkas et al. Oct 2012 A1
20120277674 Clark, III et al. Nov 2012 A1
20120310232 Erez Dec 2012 A1
20130018236 Altshuler et al. Jan 2013 A1
20130019374 Schwartz Jan 2013 A1
20130035680 Ben-Haim et al. Feb 2013 A1
20130066309 Levinson Mar 2013 A1
20130073017 Liu et al. Mar 2013 A1
20130079684 Rosen et al. Mar 2013 A1
20130116758 Levinson et al. May 2013 A1
20130116759 Levinson et al. May 2013 A1
20130150844 Deem et al. Jun 2013 A1
20130158440 Allison Jun 2013 A1
20130158636 Ting et al. Jun 2013 A1
20130166003 Johnson et al. Jun 2013 A1
20130190744 Avram et al. Jul 2013 A1
20130238062 Ron Edoute et al. Sep 2013 A1
20130245507 Khorassani Zadeh Sep 2013 A1
20130253384 Anderson et al. Sep 2013 A1
20130253493 Anderson et al. Sep 2013 A1
20130253494 Anderson et al. Sep 2013 A1
20130253495 Anderson et al. Sep 2013 A1
20130253496 Anderson et al. Sep 2013 A1
20130303904 Barthe et al. Nov 2013 A1
20130303905 Barthe et al. Nov 2013 A1
20130331914 Lee et al. Dec 2013 A1
20140005759 Fahey et al. Jan 2014 A1
20140005760 Levinson et al. Jan 2014 A1
20140067025 Levinson et al. Mar 2014 A1
20140142469 Britva et al. May 2014 A1
20140200487 Ramdas et al. Jul 2014 A1
20140200488 Seo et al. Jul 2014 A1
20140222121 Spence et al. Aug 2014 A1
20140277219 Nanda Sep 2014 A1
20140277302 Weber et al. Sep 2014 A1
20140277303 Biser et al. Sep 2014 A1
20140303697 Anderson et al. Oct 2014 A1
20150141797 Turnquist May 2015 A1
20150209174 Abreu Jul 2015 A1
20150216719 DeBenedictis et al. Aug 2015 A1
20150216720 DeBenedictis et al. Aug 2015 A1
20150216816 O'Neil et al. Aug 2015 A1
20150223975 Anderson et al. Aug 2015 A1
20150283022 Lee et al. Oct 2015 A1
20150328077 Levinson Nov 2015 A1
20150335468 Rose et al. Nov 2015 A1
20150342780 Levinson et al. Dec 2015 A1
20160051308 Pennybacker et al. Feb 2016 A1
20160051401 Yee et al. Feb 2016 A1
20160135985 Anderson May 2016 A1
20160220849 Knowlton Aug 2016 A1
20170007309 DeBenedictis et al. Jan 2017 A1
20170165105 Anderson et al. Jun 2017 A1
20170196731 DeBenedictis et al. Jul 2017 A1
20170239079 Root et al. Aug 2017 A1
20170325992 DeBenedictis et al. Nov 2017 A1
20170325993 Jimenez Lozano et al. Nov 2017 A1
20170326042 Zeng et al. Nov 2017 A1
20170326346 Jimenez Lozano et al. Nov 2017 A1
20180185081 O'Neil et al. Jul 2018 A1
20180185189 Weber et al. Jul 2018 A1
20180263677 Hilton et al. Sep 2018 A1
20180271767 Jimenez Lozano et al. Sep 2018 A1
20180310950 Yee et al. Nov 2018 A1
20190125424 DeBenedictis et al. May 2019 A1
20190142493 Debenedictis et al. May 2019 A1
Foreign Referenced Citations (175)
Number Date Country
2011253768 Jun 2012 AU
2441489 Mar 2005 CA
2585214 Oct 2007 CA
333982 Nov 1958 CH
86200604 Oct 1987 CN
2514795 Oct 2002 CN
2514811 Oct 2002 CN
1511503 Jul 2004 CN
1741777 Mar 2006 CN
1817990 Aug 2006 CN
2843367 Dec 2006 CN
2850584 Dec 2006 CN
2850585 Dec 2006 CN
200970265 Nov 2007 CN
101259329 Sep 2008 CN
101309657 Nov 2008 CN
532976 Sep 1931 DE
2851602 Jun 1980 DE
4213584 Nov 1992 DE
4224595 Jan 1994 DE
4238291 May 1994 DE
4445627 Jun 1996 DE
19800416 Jul 1999 DE
263069 Apr 1988 EP
0397043 Nov 1990 EP
0406244 Jan 1991 EP
560309 Sep 1993 EP
0598824 Jun 1994 EP
1030611 Aug 2000 EP
1201266 May 2002 EP
1568395 Aug 2005 EP
2260801 Dec 2010 EP
2289598 Mar 2011 EP
2527005 Nov 2012 EP
854937 Apr 1940 FR
2744358 Aug 1997 FR
2745935 Sep 1997 FR
2767476 Feb 1999 FR
2776920 Oct 1999 FR
2789893 Aug 2000 FR
2805989 Sep 2001 FR
387960 Feb 1933 GB
2120944 Dec 1983 GB
2202447 Sep 1988 GB
2248183 Apr 1992 GB
2263872 Aug 1993 GB
2286660 Aug 1995 GB
2323659 Sep 1998 GB
58187454 Nov 1983 JP
S6094113 Jun 1985 JP
62082977 Apr 1987 JP
63076895 Apr 1988 JP
01223961 Sep 1989 JP
03051964 Mar 1991 JP
03259975 Nov 1991 JP
04093597 Mar 1992 JP
06261933 Sep 1994 JP
07194666 Aug 1995 JP
07268274 Oct 1995 JP
09164163 Jun 1997 JP
10216169 Aug 1998 JP
10223961 Aug 1998 JP
2000503154 Mar 2000 JP
3065657 Jul 2000 JP
2001046416 Feb 2001 JP
2002125993 May 2002 JP
2002224051 Aug 2002 JP
2002282295 Oct 2002 JP
2002290397 Oct 2002 JP
2002543668 Dec 2002 JP
2003190201 Jul 2003 JP
2004013600 Jan 2004 JP
2004073812 Mar 2004 JP
2004159666 Jun 2004 JP
2005039790 Feb 2005 JP
2005065984 Mar 2005 JP
2005110755 Apr 2005 JP
2005509977 Apr 2005 JP
3655820 Jun 2005 JP
2005520608 Jul 2005 JP
2005237908 Sep 2005 JP
2005323716 Nov 2005 JP
2006026001 Feb 2006 JP
2006130055 May 2006 JP
2006520949 Sep 2006 JP
2007270459 Oct 2007 JP
2008532591 Aug 2008 JP
2009515232 Apr 2009 JP
2009189757 Aug 2009 JP
200173222 Dec 1999 KR
1020040094508 Nov 2004 KR
20090000258 Jan 2009 KR
1020130043299 Apr 2013 KR
1020140038165 Mar 2014 KR
2036667 Jun 1995 RU
532976 Nov 1978 SU
0476644 Feb 2002 TW
8503216 Aug 1985 WO
9114417 Oct 1991 WO
9300807 Jan 1993 WO
9404116 Mar 1994 WO
9623447 Aug 1996 WO
9626693 Sep 1996 WO
9636293 Nov 1996 WO
9637158 Nov 1996 WO
9704832 Feb 1997 WO
9705828 Feb 1997 WO
9722262 Jun 1997 WO
9724088 Jul 1997 WO
9725798 Jul 1997 WO
9748440 Dec 1997 WO
9829134 Jul 1998 WO
9831321 Jul 1998 WO
9841156 Sep 1998 WO
9841157 Sep 1998 WO
9909928 Mar 1999 WO
9916502 Apr 1999 WO
9938469 Aug 1999 WO
9949937 Oct 1999 WO
0044346 Aug 2000 WO
0044349 Aug 2000 WO
0065770 Nov 2000 WO
0067685 Nov 2000 WO
0100269 Jan 2001 WO
0113989 Mar 2001 WO
0114012 Mar 2001 WO
0134048 May 2001 WO
0205736 Jan 2002 WO
02102921 Dec 2002 WO
03007859 Jan 2003 WO
03078596 Sep 2003 WO
03079916 Oct 2003 WO
2004000098 Dec 2003 WO
2004080279 Sep 2004 WO
2004090939 Oct 2004 WO
2005033957 Apr 2005 WO
2005046540 May 2005 WO
2005060354 Jul 2005 WO
2005096979 Oct 2005 WO
2005112815 Dec 2005 WO
2006066226 Jun 2006 WO
2006094348 Sep 2006 WO
2006106836 Oct 2006 WO
2006116603 Nov 2006 WO
2006127467 Nov 2006 WO
2007012083 Jan 2007 WO
2007028975 Mar 2007 WO
2007041642 Apr 2007 WO
2007101039 Sep 2007 WO
2007127924 Nov 2007 WO
2007145421 Dec 2007 WO
2007145422 Dec 2007 WO
2008006018 Jan 2008 WO
2008039556 Apr 2008 WO
2008039557 Apr 2008 WO
2008055243 May 2008 WO
2008143678 Nov 2008 WO
2009011708 Jan 2009 WO
2009026471 Feb 2009 WO
2010077841 Jul 2010 WO
2010127315 Nov 2010 WO
2012012296 Jan 2012 WO
2012103242 Aug 2012 WO
2013013059 Jan 2013 WO
2013075006 May 2013 WO
2013075016 May 2013 WO
2013190337 Dec 2013 WO
2014191263 Dec 2014 WO
2015117001 Aug 2015 WO
2015117005 Aug 2015 WO
2015117026 Aug 2015 WO
2015117032 Aug 2015 WO
2015117036 Aug 2015 WO
2016028796 Feb 2016 WO
2016048721 Mar 2016 WO
Non-Patent Literature Citations (87)
Entry
“ThermaCool Monopolar Capacitive Radiofrequency, The one choice for nonablative tissue tightening and contouring”, Thermage, Inc. Tech Brochure, Nov. 30, 2005, 8 pgs.
Aguilar et al., “Modeling Cryogenic Spray Temperature and Evaporation Rate Based on Single-Droplet Analysis,” Eighth International Conference on Liquid Atomization and Spray Systems, Pasadena, CA, USA, Jul. 2000, 7 pages.
Al-Sakere, B. et al. “Tumor Ablation with Irreversible Electroporation,” PLoS One, Issue 11, Nov. 2007, 8 pages.
Alster, T. et al., “Cellulite Treatment Using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device,” Journal of Cosmetic and Laser Therapy, vol. 7, 2005, pp. 81-85.
Ardevol, A. et al., “Cooling Rates of Tissue Samples During Freezing with Liquid Nitrogen,” Journal of Biochemical and Biophysical Methods, vol. 27, 1993, pp. 77-86.
Arena, C. B et al., “High-Frequency Irreversible Electroporation (H-FIRE) for Non-Thermal Ablation Without Muscle Contraction,” BioMedical Engineering OnLine 2011,10:102, Nov. 21, 2011, 21 pgs.
Becker, S. M et al. “Local Temperature Rises Influence In Vivo Electroporation Pore Development: A Numerical Stratum Corneum Lipid Phase Transition Model,” Journal of Biomechanical Engineering, vol. 129, Oct. 2007, pp. 712-721.
Bohm, T. et al., “Saline-Enhanced Radiofrequency Ablation of Breast Tissue: an in Vitro Feasibility Study,” Investigative Radiology, vol. 35 (3), 2000, pp. 149-157.
Bondei, E et al., “Disorders of Subcutaneous Tissue (Cold Panniculitis),” Dermatology in General Medicine, Fourth Edition, vol. 1, Chapter 108, 1993, Section 16, pp. 1333-1334.
Burge, S.M et al., “Hair Follicle Destruction and Regeneration in Guinea Pig Skin after Cutaneous Freeze Injury,” Cryobiology, 27(2), 1990, pp. 153-163.
Coban, Y. K. et al., “Ischemia-Reperfusion Injury of Adipofascia I Tissue: An Experimental Study Evaluating Early Histologic and Biochemical Alterations in Rats,” Mediators of Inflammation, 2005, 5, pp. 304-308.
Del Pino, M. E. et al. “Effect of Controlled Volumetric Tissue Heating with Radiofrequency on Cellulite and the Subcutaneous Tissue of the Buttocks and Thighs,” Journal of Drugs in Dermatology, vol. 5, Issue 8, Sep. 2006, pp. 714-722.
Donski, P. K et al., “The Effects of Cooling no Experimental Free Flap Survival,” British Journal of Plastic Surgery, vol. 33, 1980, pp. 353-360.
Duck, F. A., Physical Properties of Tissue, Academic Press Ltd., chapters 4 & 5, 1990, pp. 73-165.
Duncan, W. C. et al., “Cold Panniculitis,” Archives of Dermatology, vol. 94, Issue 6, Dec. 1966, pp. 722-724.
Epstein, E. H. et al., “Popsicle Panniculitis,” The New England Journal of Medicine, 282(17), Apr. 23, 1970, pp. 966-967.
Fournier, L. et al. “Lattice Model for the Kinetics of Rupture of Fluid Bilayer Membranes,” Physical Review, vol. 67, 2003, pp. 051908-1-051908-11.
Gabriel, S. et al., “The Dielectric Properties of Biological Tissues: II. Measurements in the Frequency Range 10 Hz to 20 GHz,” Physics in Medicine and Biology, vol. 41, 1996, pp. 2251-2269.
Gage, A. “Current Progress in Cryosurgery,” Cryobiology 25, 1988, pp. 483-486.
Gatto, H. “Effects of Thermal Shocks on Interleukin-1 Levels and Heat Shock Protein 72 (HSP72) Expression in Normal Human Keratinocytes,” PubMed, Archives of Dermatological Research, vol. 284, Issue 7, 1992: pp. 414-417 [Abstract].
Hale, H. B. et al., “Influence of Chronic Heat Exposure and Prolonged Food Deprivation on Excretion of Magnesium, Phosphorus, Calcium, Hydrogen Ion & Ketones,” Aerospace Medicine, vol. 39—No. 9, Sep. 1968, pp. 919-926.
Heller Page, E. et al., “Temperature-dependent skin disorders,” Journal of the American Academy of Dermatology, vol. 18, No. 5, Pt 1, May 1988, pp. 1003-1019.
Hemmingsson, A. et al. “Attenuation in Human Muscle and Fat Tissue in Vivo and in Vitro,” Aera Radiologica Diagnosis, vol. 23, No. 2, 1982, pp. 149-151.
Henry, F. et al., “Les Dermatoses Hivernales,” Rev Med Liege, 54:11, 1999, pp. 864-866. [Abstract Attached].
Holland, DB. et al. “Cold shock induces the synthesis of stress proteins in human keratinocytes,” PubMed Journal of Investigative Dermatology; 101(2): Aug. 1993, pp. 196-199.
Holman, W. L. et al., “Variation in Cryolesion Penetration Due to Probe Size and Tissue Thermal Conductivity,” The Annals of Thoracic Surgery, vol. 53, 1992, pp. 123-126.
Hong, J.S. et al., “Patterns of Ice Formation in Normal and Malignant Breast Tissue,” Cryobiology 31, 1994, pp. 109-120.
Huang et al. “Comparative Proteomic Profiling of Murine Skin,” Journal of Investigative Dermatology, vol. 121(1), Jul. 2003, pp. 51-64.
International Search Report and Written Opinion for PCT/US2007/023492; Applicant: Zeltiq Aesthetics, Inc.; dated May 15, 2008, 7 pages.
Isambert, H. “Understanding the Electroporation of Cells and Artificial Bilayer Membranes,” Physical Review Letters, vol. 80, No. 15, 1998, pp. 3404-3707.
Kellum, R. E. et al., “Sclerema Neonatorum: Report of Case and Analysis of Subcutaneous and Epidermal-Dermal Lipids by Chromatographic Methods,” Archives of Dermatology, vol. 97, Apr. 1968, pp. 372-380.
Koska, J. et al., “Endocrine Regulation of Subcutaneous Fat Metabolism During Cold Exposure in Humans,” Annals of the New York Academy of Sciences, vol. 967, 2002, pp. 500-505.
Kundu, S. K. et al., “Breath Acetone Analyzer: Diagnostic Tool to Monitor Dietary Fat Loss,” Clinical Chemistry, vol. 39, Issue (1), 1993, pp. 87-92.
Kundu, S. K. et al., “Novel Solid-Phase Assay of Ketone Bodies in Urine,” Clinical Chemistry, vol. 37, Issue (9), 1991, pp. 1565-1569.
Kuroda, S. et al. “Thermal Distribution of Radio-Frequency Inductive Hyperthermia Using an Inductive Aperture-Type Applicator: Evaluation of the Effect of Tumor Size and Depth”, Medical and Biological Engineering and Computing, vol. 37, 1999, pp. 285-290.
Laugier, P. et al., “In Vivo Results with a New Device for Ultrasonic Monitoring of Pig Skin Cryosurgery: The Echographic Cryprobe,” The Society for Investigative Dermatology, Inc., vol. 111, No. 2, Aug. 1998, pp. 314-319.
Levchenko et al., “Effect of Dehydration on Lipid Metabolism” Ukrainskii Biokhimicheskii Zhurnal, vol. 50, Issue 1, 1978, pp. 95-97.
Lidagoster, MD et al., “Comparison of Autologous Fat Transfer in Fresh, Refrigerated, and Frozen Specimens: An Animal Model,” Annals of Plastic Surgery, vol. 44, No. 5, May 2000, pp. 512-515.
Liu, A. Y.-C et al., “Transient Cold Shock Induces the Heat Shock Response upon Recovery at 37 C in Human Cells,” Journal of Biological Chemistry, , 269(20), May 20, 1994, pp. 14768-14775.
L'vova, S.P. “Lipid Levels and Lipid Peroxidation in Frog Tissues During Hypothermia and Hibernation” Ukrainskii Biokhimicheskii Zhurnal, vol. 62, Issue 1, 1990, pp. 65-70.
Maize, J.C. “Panniculitis,” Cutaneous Pathology, Chapter 13, 1998, 327-344.
Malcolm, G. T et al., “Fatty Acid Composition of Adipose Tissue in Humans: Differences between Subcutaneous Sites,” The American Journal of Clinical Nutrition, vol. 50, 1989, pp. 288-291.
Manstein, D. et al. “A Novel Cryotherapy Method of Non-invasive, Selective Lipolysis,” LasersSurg.Med 40:S20, 2008, p. 104.
Manstein, D. et al. “Selective Cryolysis: A Novel Method of Non-lnvasive Fat Removal,” Lasers in Surgery and Medicine: The Official Journal of the ASLMS, vol. 40, 2008, pp. 595-604.
Mayoral, “Case Reports: Skin Tightening with a Combined Unipolar and Bipolar Radiofrequency Device,” Journal of Drugs in Dermatology, 2007, pp. 212-215.
Mazur, P. “Cryobiology: the Freezing of Biological Systems,” Science, 68, 1970, pp. 939-949.
Merrill, T. “A Chill to the Heart: A System to Deliver Local Hypothermia Could One Day Improve the Lives of Heart-Attack Patients,” Mechanical Engineering Magazine, Oct. 2010, 10 pages.
Miklavcic, D et al. “Electroporation-Based Technologies and Treatments,” The Journal of Membrane Biology (2010) 236:1-2, 2 pgs.
Moschella, S. L. et al., “Diseases of the Subcutaneous Tissue,” in Dermatology, Second Edition, vol. 2, 1985 Chapter 19, Section II (W.B. Saunders Company, 1980) pp. 1169-1181.
Murphy, J. V. et al., “Frostbite: Pathogenesis and Treatment” The Journal of Trauma: Injury, Infection, and Critical Care, vol. 48, No. 1, Jan. 2000, pp. 171-178.
Nagao, T. et al.,“Dietary Diacylglycerol Suppresses Accumulation of Body Fat Compared to Triacylglycerol in Men a Double-Blind Controlled Trial,” The Journal of Nutrition, vol. 130, Issue (4), 2000, pp. 792-797.
Nagle, W. A. et al. “Cultured Chinese Hamster Cells Undergo Apoptosis After Exposure to Cold but Nonfreezing Temperatures,” Cryobiology 27, 1990, pp. 439-451.
Nagore, E et al., “Lipoatrophia Semicircularis-a Traumatic Panniculitis: Report of Seven Cases and Review of the Literature,” Journal of the American Academy of Dermatology, vol. 39, Nov. 1998, pp. 879-881.
Nanda, G.S. et al., “Studies on electroporation of thermally and chemically treated human erythrocytes,” Bioelectrochemistry and Bioenergetics, 34, 1994, pp. 129-134, 6 pgs.
Narins, D.J et al. “Non-Surgical Radiofrequency Facelift”, The Journal of Drugs in Dermatology, vol. 2, Issue 5, 2003, pp. 495-500.
Nielsen, B. “Thermoregulation in Rest and Exercise,” Acta Physiologica Scandinavica Supplementum, vol. 323 (Copenhagen 1969), pp. 7-74.
Nishikawa, H. et al. “Ultrastructural Changes and Lipid Peroxidation in Rat Adipomusculocutaneous Flap Isotransplants after Normothermic Storage and Reperfusion,” Transplantation, vol. 54, No. 5, 1992, pp. 795-801.
Nurnberger, F. “So-Called Cellulite: An Invented Disease,” Journal of Dermatologic Surgery and Oncology, Mar. 1978, pp. 221-229.
Pease, G. R. et al., “An Integrated Probe for Magnetic Resonance Imaging Monitored Skin Cryosurgery,” Journal of Biomedical Engineering, vol. 117, Feb. 1995, pp. 59-63.
Pech, P. et al., “Attenuation Values, Volumes Changes and Artifacts in Tissue Due to Freezing,” Acta Radiologica ,vol. 28, Issue 6, 1987, pp. 779-782.
Peterson, L. J et al., “Bilateral Fat Necrosis of the Scrotum,” Journal of Urology, vol. 116, 1976, pp. 825-826.
Phinney, S. D. et al., “Human Subcutaneous Adipose Tissue Shows Site-Specific Differences in Fatty Acid Composition,” The American Journal of Clinical Nutrition, vol. 60, 1994, pp. 725-729.
Pierard, G.E. et al., “Cellulite: From Standing Fat Herniation to Hypodermal Stretch Marks,” The American Journal of Dermatology, vol. 22, Issue 1, 2000, pp. 34-37, [Abstract].
Pope, K. et al. “Selective Fibrous Septae Heating: An Additional Mechanism of Action for Capacitively Coupled Monopolar Radiofrequency” Thermage, Inc. Article, Feb. 2005, 6pgs.
Quinn, P. J. “A Lipid-Phase Separation Model of Low-Temperature Damage to Biological Membranes,” Cryobiology, 22, 1985, 128-146.
Rabi, T. et al., “Metabolic Adaptations in Brown Adipose Tissue of the Hamster in Extreme Ambient Temperatures,” American Journal of Physiology, vol. 231, Issue 1, Jul. 1976, pp. 153-160.
Renold, A.E. et al. “Adipose Tissue” in Handbook of Physiology, Chapter 15, (Washington, D.C., 1965) pp. 169-176.
Rossi, A. B. R. et al. “Cellulite: a Review,” European Academy of Dermatology and Venereology, 2000, pp. 251-262, 12 pgs.
Rubinsky, B. “Principles of Low Temperature Cell Preservation,” Heart Failure Reviews, vol. 8, 2003, pp. 277-284.
Rubinsky, B. et al., “Cryosurgery: Advances in the Application of low Temperatures to Medicine,” International Journal of Refrigeration, vol. 14, Jul. 1991, pp. 190-199.
Saleh, K.Y. et al., “Two-Dimensional Ultrasound Phased Array Design for Tissue Ablation for Treatment of Benign Prostatic Hyperplasia,” International Journal of Hyperthermia, vol. 20, No. 1, Feb. 2004, pp. 7-31.
Schoning, P. et al., “Experimental Frostbite: Freezing Times, Rewarming Times, and Lowest Temperatures of Pig Skin Exposed to Chilled Air,” Cryobiology 27, 1990, pp. 189-193.
Shephard, R. J. “Adaptation to Exercise in the Cold,” Sports Medicine, vol. 2, 1985, pp. 59-71.
SIGMA-ALDRICH “Poly(ethylene glycol) and Poly(ethylene oxide),” http://www.sigmaaldrich.com/materials-science/materialscience-;products.htmi?TablePage=2020411 0, accessed Oct. 19, 2012.
Smalls, L. K. et al. “Quantitative Model of Cellulite: Three Dimensional Skin Surface Topography, Biophysical Characterization, and Relationship to Human Perception,” International Journal of Cosmetic Science, vol. 27, Issue 5, Oct. 2005, 17 pgs.
Thermage, News Release, “Study Published in Facial Plastic Surgery Journal Finds Selective Heating of Fibrous Septae Key to Success and Safety of Thermage ThermaCool System,” Jun. 20, 2005, 2 pages.
Vallerand et al. “Cold Stress Increases Lipolysis, FFA Ra and TG/FFA Cycling in Humans,” Aviation, Space, and Environmental Medicine 70(1), 1999, pp. 42-50.
Wang, X. et al., “Cryopreservation of Cell/Hydrogel Constructs Based on a new Cell-Assembling Technique,” Sep. 5, 2009, 40 pages.
Wharton, D. A. et al., “Cold Acclimation and Cryoprotectants in a Freeze-Tolerant Antarctic Nematode, Panagrolaimus Davidi,”, Journal of Comparative Physiology, vol. 170, No. 4, Mar. 2000, 2 pages.
Winkler, C. et al., “Gene Transfer in Laboratory Fish: Model Organisms for the Analysis of Gene Function,” in Transgenic Animals, Generation and Use (The Netherlands 1997), pp. 387-395.
Young, H. E. et al. “Isolation of Embryonic Chick Myosatellite and Pluripotent Stem Cells” The Journal of Tissue Culture Methods, vol. 14, Issue 2, 1992, pp. 85-92.
Zouboulis, C. C. et al., “Current Developments and Uses of Cryosurgery in the Treatment of Keloids and Hypertrophic Scars,” Wound Repair and Regeneration, vol. 10, No. 2, 2002, pp. 98-102.
Hernan, P. et al., “Study for the evaluation of the efficacy of Lipocryolysis (EEEL)”, Nov. 30, 2011.
Hernan, R. P., “A Study to Evaluate the Action of Lipocryolysis”, 33(3) CryoLellers, 2012, pp. 176-180.
Jalian, H. R. et al., “Cryolipolysis: A Historical Perspective and Current Clinical Practice”, 32(1) Semin. Cutan. Med. Surg., 2013, pp. 31-34.
Zelickson, B et al., “Cryolipolysis for Noninvasive Fat Cell Destruction: Initial Results from a Pig Model”, 35 Dermatol. Sug., 2009, pp. 1-9.
Disclosure re: “Method and Apparatus for Regional Fat Reduction Using Controlled and Sustained Cooling of Skin Surface,” Oct. 12, 2006, 7 pages.
Related Publications (1)
Number Date Country
20150328077 A1 Nov 2015 US
Continuations (2)
Number Date Country
Parent 13471826 May 2012 US
Child 14808245 US
Parent 11558046 Nov 2006 US
Child 13471826 US